Nemactil (Periciazine)

• Nemactil (periciazine) is used in the phenothiazine antipsychotic class to treat several psychiatric conditions.
• Schizophrenia: reduces positive and negative symptoms and helps prevent relapse.
• Acute psychotic episodes: alleviates hallucinations, delusions and agitation during crisis periods.
• Manic episodes in bipolar disorder: stabilizes mood and diminishes elevated energy and risky behavior.

• Periciazine exerts its antipsychotic effect primarily by antagonizing dopamine D2 receptors in the central nervous system, thereby reducing dopaminergic neurotransmission. It also blocks other receptors such as histamine H1, muscarinic acetylcholine, and alpha‑adrenergic sites, contributing to its sedative and anticholinergic properties, which together help control psychotic symptoms and mood disturbances.

Periciazine may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

• Sedation or drowsiness
• Extrapyramidal symptoms such as tremor or rigidity
• Dry mouth and constipation
• Blurred vision
• Weight gain
• Orthostatic hypotension

Serious or Rare Side Effects

• Neuroleptic malignant syndrome
• Tardive dyskinesia
• Severe hypotension or cardiac arrhythmia
• Agranulocytosis
• Seizures
• Hepatic dysfunction

• When prescribing periciazine, clinicians should observe several safety considerations to minimize risk.
• Extrapyramidal symptoms: monitor for tremor, rigidity, and involuntary movements.
• Cardiovascular effects: assess blood pressure and heart rhythm, especially in patients with pre‑existing conditions.
• Seizure risk: use cautiously in individuals with a history of seizures.
• Elderly patients: avoid use in dementia‑related psychosis due to increased mortality.
• Abrupt discontinuation: taper gradually to prevent withdrawal phenomena.
• Store at ambient temperature: keep in original packaging, protect from moisture and light.

Periciazine interacts with several medicines; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

• CNS depressants (e.g., benzodiazepines, opioids): may enhance sedation and respiratory depression.
• Anticholinergic agents: increase risk of severe anticholinergic toxicity.
• QT‑prolonging drugs (e.g., certain antiarrhythmics): heighten risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• Antihypertensives: additive hypotensive effect may require dose adjustment.
• Antidiabetic medications: periciazine can affect glucose control.
• Other antipsychotics: combined use may increase extrapyramidal and metabolic side effects.